Clinical Audit Report Example & Template

Why download a blank template?

Traditional templates still require hours of manual writing. ClinicalAuditAI generates the completed report automatically using your monitoring findings.

Feature	Traditional Template	ClinicalAuditAI
Document Type	Blank document	Complete report
Writing Method	Manual writing	AI-assisted generation
Formatting	Manual formatting	Structured output
CAPA Generation	Manual CAPA	Suggested CAPA

See What ClinicalAuditAI Can Generate

Don't stop at a blank clinical audit template. Generate your first two audit chapters free from your own clinical findings, monitoring notes or compliance observations.

Generate Free Chapters 1–2

Example Audit Input

Below is an example of raw monitoring findings uploaded into ClinicalAuditAI.

• Patient missed scheduled Visit 6.
• Informed consent signed after screening.
• Serious adverse event reported outside reporting timeline.
• Missing laboratory documentation.
• Temperature excursion recorded without investigation.
• Protocol deviation not documented.

Who should use this template?

• Hospitals
• Clinical Research Organisations (CROs)
• Sponsors
• Clinical Research Sites
• Quality Assurance Teams
• Compliance Managers
• Clinical Auditors

1.1 Introduction

This report details findings from a routine clinical compliance audit conducted at a clinical research site. The objective of the audit is to evaluate adherence to regulatory requirements, protocol obligations, ethical standards, human subject protections, and clinical data integrity expectations.

The review included source documentation, regulatory binders, staff training records, informed consent documentation, adverse event handling processes, and standard operating procedures (SOPs).

Findings are categorized using severity levels including [CRITICAL], [MAJOR], and [MINOR].

1.2 Audit Scope

The scope encompasses all active clinical trial protocol documentation, subject records, laboratory logs, pharmacy dispensation records, and site regulatory files covering the period from initiation to the current audit date.

1.3 Audit Objectives

To verify protocol compliance, evaluate subject safety and human subject protection measures, ensure trial data integrity, and assess site operational readiness for regulatory inspections.

1.4 Methodology

Randomized retrospective source document verification (SDV), interviews with key clinical trial personnel, systematic review of essential document binders, and automated compliance risk classification.

1.5 Applicable Regulations

ICH-GCP E6(R2), 21 CFR Part 11, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, EU Clinical Trials Regulation (CTR) 536/2014, and local institutional review board (IRB) / ethics committee directives.

1.6 Inspection Standards

FDA Compliance Program Guidance Manual (CPGM), MHRA Good Clinical Practice Inspection Model, and EMA GCP Inspection Guidelines.

1.7 Document Sources

Electronic Case Report Forms (eCRF), Source Data Documents (Medical Records), Informed Consent Documents, Investigational Medicinal Product (IMP) Logs, Safety Logs, and Site Master Files.

1.8 Executive Summary

The audit identified substantial compliance risks requiring corrective action. Major deficiencies were identified in informed consent handling, subject visit management, adverse event reporting, and protocol adherence.

Unsigned Informed Consent Form

During review of study documentation, informed consent records were found incomplete before study procedures.

Severity: [CRITICAL]

Regulatory Basis: ICH-GCP E6(R2), 21 CFR Part 50 and ethics requirements.

Evidence: Subject 104 underwent screening procedures on 12-Jan-2026, but the Informed Consent Form was dated 14-Jan-2026 without a investigator signature on the primary consent line.

Risk: Failure to obtain documented consent may compromise patient rights, ethics, and data validity.

Impact: High risk of regulatory non-compliance during inspections and potential invalidation of subject data for protocol efficacy populations.

Recommendation: Immediately halt study procedures for affected subject, re-consent using current IRB-approved form, and notify IRB/Ethics Committee of protocol violation.

CAPA: Implement mandatory two-person verification of consent documentation prior to initiating any screening procedures; re-train all study coordinators on 21 CFR Part 50 requirements.

Responsible Owner: Principal Investigator / Lead Clinical Research Coordinator

Target Completion Date: 14 Days from Audit Closure

Verification Method: 100% QA audit of subject consent logs and signed re-consent documentation.

---

Adverse Event Not Reported

Review of source documentation revealed an adverse event documented in medical records but missing from sponsor reporting systems.

Severity: [CRITICAL]

Regulatory Basis: 21 CFR 312.32, ICH-GCP E6(R2) Section 4.11.

Evidence: Hospitalization record dated 02-Feb-2026 for Subject 112 was noted in medical records for Grade 3 elevated liver enzymes, but was not transmitted to safety database within the mandated 24-hour window.

Risk: Delayed reporting may compromise participant safety, regulatory compliance, and study integrity.

Impact: Failure to report Serious Adverse Events (SAEs) compromises safety monitoring across the entire trial and incurs severe regulatory penalties.

Recommendation: Submit expedited SAE report to Sponsor and IRB immediately with full medical narrative.

CAPA: Conduct root-cause analysis on safety communication workflows; implement automated daily EMR alert filters for trial subject hospitalizations.

Responsible Owner: Medical Monitor / Sub-Investigator

Target Completion Date: Immediate (Within 24 Hours)

Verification Method: Reconciliation audit between site source documents and safety database entries.

Frequently Asked Questions

Related Resources

• Clinical Audit Report Example
• How to Automate Clinical Audits
• Clinical AI Auditing Best Practices